CNS disorders are often treated ineffectively by trial-and-error, causing prolonged patient distress and high healthcare costs. Neumarker aims to transform the treatment of CNS disorders through its cutting-edge brain biomarker discovery platform, powered by AI. By identifying predictive brain biomarkers, we can personalize treatment for each patient and accelerate drug development by efficient clinical trials. Neumarker is committed to advancing precision neuromedicine through collaborations with drug developers, clinicians and academic researchers.
| Website | http://neumarker.ai/ |
| Employees | 21 (12 on RocketReach) |
| Founded | 2022 |
| Industry | Mental Health Care |
| Keywords | Biomarker Discovery, Cns Disorders, Neurological Disorders, Drug Discovery, Neuroscience, Therapeutic Targets, Treatment Optimization, Precision Medicine, Brain Health, Digital Biomarkers, Patient Monitoring, Data Analytics, Artificial Intelligence, Machine Learning, Diagnostic Tools, Clinical Trials, Big Data, Healthcare Technology, Healthtech |
| Competitors | PathAI, Zebra Medical Vision Ltd, Qure.ai, Aidoc, Siemens Healthineers, IBM, Freespira, Google Health, Enlitic, CureMetrix +32 more (view full list) |
Looking for a particular Neumarker Inc. employee's phone or email?
Ken Wang is the Co-Founder, CEO of Neumarker Inc..
12 people are employed at Neumarker Inc..
Neumarker Inc. is based in Palo Alto, California.